Evidence map›Paper›PMID 32953243›Full record

ArticleTranslational vision science & technology2020

Comparative Analysis of Multiplex Platforms for Detecting Vitreous Biomarkers in Diabetic Retinopathy.

Ricardo Lamy, Suzette Farber-Katz, Franklin Vives, Gulesi Ayanoglu, Tong Zhao, Yi Chen, Sawarin Laotaweerungsawat, Dahui Ma, Audrey Phone, Catherine Psaras and 4 more

Open access · goldAbstract read
In one paragraph

Article in Translational vision science & technology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 3 countries.

Ricardo LamyDepartment of Ophthalmology, University of California, San Francisco, San Francisco, CA, USA.
Suzette Farber-KatzMerck & Co., Inc., South San Francisco, CA, USA.
Franklin VivesMerck & Co., Inc., South San Francisco, CA, USA.
Gulesi AyanogluMerck & Co., Inc., South San Francisco, CA, USA.
Tong ZhaoDepartment of Ophthalmology, University of California, San Francisco, San Francisco, CA, USA.
Yi ChenDepartment of Ophthalmology, University of California, San Francisco, San Francisco, CA, USA.
Sawarin LaotaweerungsawatDepartment of Ophthalmology, University of California, San Francisco, San Francisco, CA, USA.
Dahui MaDepartment of Ophthalmology, University of California, San Francisco, San Francisco, CA, USA.
Audrey PhoneDepartment of Ophthalmology, University of California, San Francisco, San Francisco, CA, USA.
Catherine PsarasDepartment of Ophthalmology, University of California, San Francisco, San Francisco, CA, USA.
Nina Xiaoyan LiMerck & Co., Inc., South San Francisco, CA, USA.
Santosh SutradharMerck & Co., Inc., South San Francisco, CA, USA.
Paul E CarringtonMerck & Co., Inc., South San Francisco, CA, USA.
Jay M StewartDepartment of Ophthalmology, University of California, San Francisco, San Francisco, CA, USA.
Merck & Co., Inc., Rahway, NJ, USA (United States) · USUniversity of California, San Francisco · USSan Francisco General Hospital · USCharoenkrung Pracharak Hospital · THShenzhen University · CN

Funding

Rapid-Prototyping and Design CoreP30EY002162 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ULLIAN, ERIK M · 1985 to 2024
$16.8M
Ultrasound-enhanced corneal drug deliveryR01EY024004 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEWART, JAY MICHAEL · 2017 to 2020
$1.6M
NEI NIH HHS P30 EY002162NEI NIH HHS R01 EY024004
6 · The paper itself

Abstract

Purpose: To evaluate the feasibility of using the Proximity Extension Assay (PEA) platform to detect biomarkers in vitreous and to compare the findings with results obtained with an electrochemiluminescent (ECL) sandwich immunoassay. Methods: Vitreous samples from patients with proliferative diabetic retinopathy (PDR) and non-diabetic controls were tested using two different proteomics platforms. Forty-one assays were completed with the ECL platform and 459 with the PEA platform. Spearman's rank correlation coefficient ( Results: Three hundred sixty-six PEA assays detected the tested protein in at least 25% of samples, and the difference in protein abundance between PDR and controls was statistically significant for 262 assays. Seventeen ECL assays yielded a detection rate ≥ 25%, and the difference in protein concentration between PDR and controls was statistically significant for 13 proteins. There was a subset of proteins that were detected by both platforms, and for those the Spearman's correlation coefficient was higher than 0.8. Conclusions: PEA is suitable for the analysis of vitreous samples, showing a strong correlation with the ECL platform. The detection rate of PEA panels was higher than the panels tested with ECL. The levels of several proinflammatory and angiogenic cytokines were significantly higher in PDR vitreous compared to controls. Translational Relevance: This study provides new information on the yields of small-volume assays that can detect proteins of interest in ocular specimens, and it identifies patterns of cytokine dysregulation in PDR.

Indexed as

Diabetes MellitusDiabetic RetinopathyBiomarkersCytokinesHumansProteomicsVitreous BodyBiomarkersCytokinescytokine, biomarkervitreous

Identifiers

PMID32953243
PMCPMC7476659
OpenAlexW3082655451

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.